Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease